The use of the recombinant influenza vaccine can prevent a substantial number of influenza-related hospitalizations among ...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ...

A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune ...

Hyderabad: Shilpa Medicare Limited, a pharmaceutical and biotechnology company, has announced that its 100 percent subsidiary ...

A recombinant protein therapy is produced through recombinant DNA technology, which involves inserting the DNA encoding the protein into bacterial or mammalian cells, expressing the protein in ...

Huonslab announced the successful completion of patient enrollment in its pivotal phase 1 clinical trial of Hydizyme.

Shilpa Biocare Private Limited has entered into a strategic partnership with Orion Corporation out-licensing its flagship ...

Traditional elastin replacements fail due to poor absorption and structural inaccuracy. Arelastin®’s dual ...

Industrial fermentation using bacteria, yeast and other microbes to produce specific products has the potential to reduce ...

Despite the therapeutic benefits of IgM antibodies a major technological drawback has been identified in comparison to the classical IgG molecule. Recombinant production of this immunoglobulin class ...

Orion enters agreement with Shilpa Medicare to commercialise recombinant human albumin in European market: Espoo, Finland Monday, May 26, 2025, 11:00 Hrs [IST] Orion Corporation, ...